Antibody-drug conjugates (ADCs) continue to expand treatment options across multiple cancer types, with several established agents and new approvals shaping clinical practice. In an interview with Oncology Nursing News, Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, a nurse practitioner at Sarah Cannon Research Institute in Nashville, Tennessee, highlighted key ADCs currently in use and those on the horizon.